BUZZ-Morgan Stanley sees EPS accretion to CSL's buyout of Vifor Pharma
** Morgan Stanley says CSL's acquisition of Vifor Pharma is expected to imply a 6.6% earnings-per-share accretion to its FY23 estimate
** The biotechnology firm said on Tuesday acquisition of Vifor Pharma AG is expected to be completed by Aug 9 [nFWN2ZD61S]
** Broker sees merit in buyout due to diversification of co's portfolio against potential medium- to long-term disruption from 'FcRn' and influenza vaccine manufactured by mRNA technology, among others
** Broker estimates CSL's plasma collections to return to pre-pandemic levels in March-quarter 2022 and expects volumes to rise more than 20% pcp in FY23
** Brokerage keeps "overweight" rating on the stock, sets a price target of A$312.00
** Fourteen of 15 analysts rate the stock "buy" or higher, one "hold" and none "sell" or lower; their median PT is A$327.63
– Refinitiv data
** CSL shares drop 0.4%, in line with a weak broader market <.AXJO>, which is down 0.5%
** CSL stock up 2.1% this year, as of last close
copy and past
(20min delay)